Outlook Therapeutics Incs. (OTLK) PT Raised to $5 at Ascendiant Capital
- Wall Street slides as virus spike hits travel stocks
- Kansas City Southern (KSU) Soars as Bidding War Brews After Canadian National Railway (CNI) Makes a $33.7 Billion Offer
- Analysts Positive, Raise PTs as IBM (IBM) Tops Market Estimates and Reaffirms Guidance
- Boeing (BA) Down 3% After CFO - Aged 54 - Retires, Seen as an 'Odd' Move
- Tesla (TSLA): Problems in China Mounting as Communist Party Officials Ask Company to 'Respect Chinese Consumers and Comply with Local Laws'
Ascendiant Capital analyst Edward Woo raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $5.00 (from $3.50) while maintaining a Buy rating.
You May Also Be Interested In
- Brewin Dolphin Holdings Plc. (BRW:LN) (BDNHF) PT Raised to GBP3.90 at Berenberg
- IAMGOLD Corp (IMG:CN) (IAG) PT Lowered to Cdn$7.25 at Stifel Canada
- Ten Entertainment Group Plc. (TEG:LN) PT Raised to GBP3.25 at Berenberg
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!